A 42-year-old woman with Stage IA grade 1 endometrioid endometrial carcinoma (confined to endometrium, no myometrial invasion) desires future fertility. Endocrine therapy with high-dose progestins is planned. Which treatment regimen and response assessment interval is currently recommended?
- A Norethindrone acetate 10 mg/day for 3 months, then annual surveillance
- B Medroxyprogesterone acetate 500 mg/day orally or LNG-IUS with repeat biopsy at 3-month intervals; hysterectomy after childbearing complete ✓
- C GnRH agonist for 6 months followed by ART for fertility; no progestin required
- D Letrozole + levonorgestrel IUS combination for 12 months before assessing response
Explanation
Fertility-sparing management of grade 1, stage IA endometrioid endometrial carcinoma (no myometrial invasion, no extrauterine disease) uses high-dose continuous progestins — most commonly MPA 500 mg/day orally or 1000 mg/day, or megestrol acetate 160 mg/day — along with LNG-IUS as an adjunct (LNG-IUS provides high local endometrial progestin levels). Response is assessed by repeat endometrial biopsy every 3 months; complete response rate is ~70-80% by 6 months. Concurrent treatment of PCOS/insulin resistance with metformin improves complete response rate. Once childbearing is complete, definitive hysterectomy (total) with bilateral salpingo-oophorectomy is recommended. ART/IVF can be attempted after documented complete remission.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.